- Home
- DYN vs DBD Comparison
DYN vs DBD Comparison
Compare DYN & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYN | DBD |
|---|---|---|
| Founded | 1984 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DYN | DBD |
|---|---|---|
| Price | $20.13 | $87.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | $37.00 | ★ $90.00 |
| AVG Volume (30 Days) | ★ 1.8M | 630.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 677.27 |
| EPS | N/A | ★ 2.54 |
| Revenue | N/A | ★ $3,805,700,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | N/A | $3.25 |
| P/E Ratio | ★ N/A | $34.93 |
| Revenue Growth | N/A | ★ 1.46 |
| 52 Week Low | $8.25 | $41.05 |
| 52 Week High | $25.00 | $88.91 |
Technical Indicators
Market Signals| Indicator | DYN | DBD |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 69.37 |
| Support Level | $18.32 | $68.51 |
| Resistance Level | $21.00 | N/A |
| Average True Range (ATR) | 1.08 | 2.62 |
| MACD | 0.15 | 0.90 |
| Stochastic Oscillator | 66.31 | 91.23 |
Price Performance
Historical ComparisonAbout DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.